Production (Stage)
COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -13.93% | -13.93% | -7.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -13.93% | -13.93% | -7.30% |
| Cost of Revenue | -- | -- | 226.69% | 226.69% | 293.02% |
| Gross Profit | -- | -- | -92.93% | -92.93% | -91.95% |
| SG&A Expenses | -- | -- | -72.63% | -11.30% | -45.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -64.72% | -41.66% | -65.82% |
| Operating Income | -- | -- | 110.02% | 66.39% | 96.17% |
| Income Before Tax | -- | -- | 92.46% | 92.46% | 97.53% |
| Income Tax Expenses | -- | -- | -465.81% | -465.81% | -1,864.10% |
| Earnings from Continuing Operations | -- | -- | 102.73% | 102.73% | 105.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | 102.73% | 102.73% | 105.04% |
| EBIT | -- | -- | 110.02% | 66.39% | 96.17% |
| EBITDA | -- | -- | 132.00% | 84.51% | 110.38% |
| EPS Basic | -- | -- | 79.33% | 79.34% | 84.10% |
| Normalized Basic EPS | -- | -- | 81.76% | 50.58% | 67.48% |
| EPS Diluted | -- | -- | 79.32% | 79.32% | 84.09% |
| Normalized Diluted EPS | -- | -- | 81.76% | 50.58% | 67.48% |
| Average Basic Shares Outstanding | -- | -- | 47.48% | 47.50% | 57.70% |
| Average Diluted Shares Outstanding | -- | -- | 47.48% | 47.50% | 57.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |